newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

biotech / news / / STAT

Clear blue skies and chilly breezes greet us today.

Eli Lilly's gene-editing therapy reduced LDL cholesterol by 62% in a Phase 1 trial.

KEY POINTS
COMPANIES
Read the full story on STAT →
Share X LinkedIn

Summarized by Newsio from STAT. How we summarize →